Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 827 results for "eli lilly"

Experimental Alzheimer's drug shows some benefit
Malta Independent Daily

Experimental Alzheimer's drug shows some benefit

The U.S. drug firm, Eli Lilly & Co., reported Wednesday that an experimentalmedicationmight slow mild Alzheimer's if people take it early enough, one of a handful of drugs in late-stage testing in the frustrating hunt for a better treatment. The ... Malta Independent Daily, 15 hours ago

328 images for eli lilly

SleekMoney, 4 days ago, 4 days ago, 4 days ago
Bidness Etc, 5 days ago
ClinicSpace, 2 days ago
Savannah Morning News, 6 days ago
Star-Telegram, 1 week ago
Florida Times-Union, 6 days ago
Proactive Investors USA, 4 days ago
Jutia Group, 2 days ago

Eli Lilly to continue evacetrapib phase 3 trial

Eli Lilly and Company, a global healthcare leader, has accepted the recommendation of the ACCELERATE study data monitoring committee to continue the phase 3 trial of the investigational medicine evacetrapib, based on data from an interim futility ...
 PharmaBiz1 day ago Market Response to Biogen's and Eli Lilly's Alzheimer's Drugs  Yahoo! Finance1 day ago Healthcare Stocks Buzz- Eli Lilly (LLY), Array Biopharma (ARRY), Opko Health (OPK), Keryx Biopharmaceuticals (KERX)  Techsonian16 hours ago Lilly Reports Second-Quarter 2015 Results, Revises 2015 Financial Guidance  FierceBiotech1 day ago
Mideast Time

Eli Lilly and PT Raised to $93.00 (LLY)

Research analysts at Leerink Swann raised their price objective on shares of Eli Lilly and (NYSE:LLY) from $92.00 to $93.00 in a report released on Monday, Analyst Ratings.Net reports. The firm currently has an outperform rating on the stock.
 Mideast Time12 hours ago Eli Lilly and Receives $86.29 Average Price Target from Analysts (NYSE:LLY)  SleekMoney16 hours ago Eli Lilly and Company (NYSE:LLY) Had Its Target Price per Share Upgraded by Equity Analysts at SunTrust Robinson Humphrey to $98.00  Octafinance1 day ago SunTrust Increases Eli Lilly and Price Target to $98.00 (LLY)  Ticker Report2 days ago

Watch for Shares of Eli Lilly (LLY) to Approach Resistance at $85.31

Shares of Eli Lilly (NYSE:LLY) have bullishly opened above the pivot of $84.04 today and have reached the first resistance level of $84.75. Analysts will be watching for a cross of the next upside pivot targets of $85.31
 Individual.com1 day ago Eli Lilly (LLY) Breaks Through Resistance at $87.66  Individual.com1 week ago

Analyst's Key Takeaways From Eli Lilly, Bristol-Myer Squibb's Latest Conference Calls

In separate reports published Thursday, Evercore-ISI's Biotechnology analyst Mark Schoenebaum dissected Eli Lilly and Co (NYSE: LLY) and Bristol-Myers Squibb Co (NYSE: BMY)'s conference call following the release of their quarterly results. Here ...
 Benzinga.com6 days ago Eli Lilly CEO: Obamacare out-of-pocket costs high  Yahoo! Finance6 days ago Eli Lilly CEO Explains The Reasons Behind The $0.16 EPS Beat  Fat Pitch Financials6 days ago Eli Lilly, Biogen shares mixed on Alzheimer's studies  Yahoo! UK and Ireland1 week ago

Eli Lilly posts 2Q profit, results top Wall Street estimates

INDIANAPOLIS Eli Lilly and Co. (LLY) on Thursday reported second-quarter earnings of $600.8 million. The Indianapolis-based company said it had net income of 56 cents per share. Earnings, adjusted for non-recurring costs, were 90 cents per ...
 FOXBusiness.com6 days ago Eli Lilly Raises 2015 Forecast After Profit Tops Estimates  Bloomberg6 days ago Lilly tops Street 2Q forecasts  FOXBusiness.com6 days ago Eli Lilly tops Street 2Q forecasts, raises outlook  Yahoo! UK and Ireland6 days ago
Jutia Group

Lilly continues test of HDL cholesterol drug, on panel's advice

July 27 (Reuters) - Eli Lilly and Co on Monday said it would continue a large study of its high-profile experimental drug to raise "good" HDL cholesterol and lower "bad" LDL cholesterol, acting on the recommendation of a data monitoring ...
 Yahoo! Finance2 days ago Stock Update (NYSE:LLY): Lilly continues test of HDL cholesterol drug, on panel's advice  Market Pulse Navigator2 days ago

BRIEF-Lilly CEO says best use of money is internal company research

Eli Lilly And Co * CEO says company expects to launch Synjardy diabetes drug in U.S. this year * Lilly CEO says there is a "bubble" in prices of smaller biotech companies * Lilly CEO says company unwilling to pay inflated prices for "hot ...
 Reuters6 days ago Video: Eli Lilly CEO beats Street, raises forecast: CEO  NBCNews.com6 days ago

Eli Lilly therapy raises hope at Alzheimer's conference

The eyes of patients and investors turned in hope to the Alzheimer's Association International Conference to see if antibodies from Biogen and Eli Lilly can slow the disease's progress and the latter fared best. At the conference in Washington ...
 Pharma Field6 days ago Alzheimer's Conference Tackles Eli Lilly's Salanezumab, Biogen's Aducanumab Which Target Amyloid Plaque In Brain  International Business Times Australia1 week ago

Eli Lilly's breakthrough Alzheimer's drug

New data from Eli Lilly shows that if used early enough, its experimental drug, solanezumab, slows down symptoms of Alzheimer's disease. Bobbi week ago 01:29Eli Lilly hopeful about their new Alzheimer drug  USA Today1 week ago Eli-Lilly's drug puts brakes on Alzheimer's  European Pharmaceutical Manufacturer1 week ago Reuters Video: Eli Lilly's breakthrough Alzheimer's drug  Malay Mail6 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - eli lilly
Get updated on latest news & your favorite topics right in your inbox!
More     Less